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Background. Nitric oxide (NO) donors are a candidate treatment for acute stroke and two trials have suggested that they might
improve outcome if administered within 4–6 hours of stroke onset. We assessed the safety and efficacy of NO donors using
individual patient data (IPD) from completed trials.Methods. Randomised controlled trials of NO donors in patients with acute or
subacute stroke were identified and IPD sought from the trialists.The effect of NO donor versus control on functional outcome was
assessed using the modified Rankin scale (mRS) and death, by time to randomisation. Secondary outcomes included measures of
disability, mood, and quality of life. Results. Five trials (4,197 participants) were identified, all involving glyceryl trinitrate (GTN).
Compared with control, GTN lowered blood pressure by 7.4/3.3mmHg. At day 90, GTN did not alter any clinical measures.
However, in 312 patients randomised within 6 hours of stroke onset, GTN was associated with beneficial shifts in the mRS (odds
ratio (OR) 0.52, 95% confidence interval (CI) 0.34–0.78) and reduced death (OR0.32, 95%CI 0.14–0.78).Conclusions.NOdonors do
not alter outcome in patients with recent stroke. However, when administered within 6 hours, NO donors might improve outcomes
in both ischaemic and haemorrhagic stroke.
1. Introduction
Existing evidence-based treatment options for patients with
acute ischaemic stroke may be categorised as those with
significant efficacy but limited utility, such as intravenous
thrombolysis, thrombectomy, and hemicraniectomy [1–6];
those with limited efficacy but wide utility, for example,
aspirin [7]; and stroke unit care with intermediate efficacy
and very wide utility [8]. There are no definitive treatments
for patients with spontaneous intracerebral haemorrhage
(ICH) although very early blood pressure (BP) lowering
may be effective and is recommended in guidelines [9, 10].
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Hence, there is an urgent need for new interventions that
will improve outcome after either ischaemic or haemorrhagic
stroke.
Nitric oxide (NO) is a nonorganic gas that has multiple
roles in human physiology including vasodilation, BP regula-
tion, antiplatelet and antileucocyte activity, and neurotrans-
mission [11–14]. Circulating NO levels are low in acute stroke
[15, 16] and so immediate supplementationmight help restore
homeostasis through effects on lowering blood pressure,
improving cerebral and collateral blood flow, prevention
of microthrombosis, reduction of leukocyte adhesion, anti-
inflammatory effects, and neuroprotection. NO donors have
been studied in animal models of stroke and exhibited
time-dependent therapeutic properties [17]. In view of its
physiological properties and potential effects in experimental
stroke, NO is a candidate treatment for patients with acute
stroke [18].
Two NO donors have been assessed in patients with
acute or recent stroke. In a small and uncontrolled study,
sodium nitroprusside, a spontaneous NO donor, reduced
BP and platelet function and did not alter cerebral blood
flow (CBF) [19]. However, the NO donor studied most is
glyceryl trinitrate (GTN), an organic nitrate licensed for the
management of angina. Here, we report a systematic review
of the safety and efficacy of NO donors in acute stroke using
individual patient data from randomised controlled trials.
Since NO donors might be beneficial when administered
early, as seen in preclinical studies [17], a small clinical
trial [20], and a prespecified subgroup of a large trial [21],
we hypothesised that very early administration (defined as
randomisation within 6 hours of onset) might be especially
effective in improving clinical outcome.
2. Methods
2.1. Ethics. No research ethics committee approval was
needed for this study since anonymised individual patient
data came from completed and published trials, each ofwhich
had their own national and local approvals and consent.
2.2. Selection Criteria and Search Strategy. Completed ran-
domised controlled trials that investigated the effect of a NO
donor versus control (placebo or absence of a NO donor)
in adult patients with acute or subacute stroke (ischaemic
stroke or ICH, within 1 week/168 hours of onset) were sought
with searches of electronic databases including the Cochrane
Stroke Group Trials Register (searched October 2014),
Cochrane Database of Systematic Reviews (CDSR), and the
Cochrane Central Register of Controlled Trials (CENTRAL,
Cochrane Library Issue 2, 2014), MEDLINE (Ovid) (1966 to
May 2014), EMBASE (Ovid) (1974 toMay 2014), Science Cita-
tion Index (ISI, Web of Science, 1981 to May 2014), and the
Stroke Trials Registry (http://www.strokecenter.org/trials/)
(May 2014). Separate search strategies were developed for
each database (supplemental search criteria). Reference lists
in earlier reviews of NO donors and BP lowering [22] and
identified trial publications were also checked for additional
studies. Whereas duplicate publications were identified,
data from the primary report were used. Publications could
be in any language.
2.3. Outcomes. Theprimary outcome was dependency at end
of follow-up assessed using the 7-level modified Rankin scale
(mRS, normal/no symptoms = 0, severe dependency = 5, and
dead = 6). Secondary measures during or at the end of ran-
domised treatment included haemodynamics (BP, heart rate);
deterioration; recurrence; impairment (Scandinavian Stroke
Scale, SSS); headache; symptomatic hypotension; and hyper-
tension of clinical importance. Hospital measures comprised
hospital discharge disposition and length of stay. End of
follow-up outcomes included disability/activities of daily liv-
ing (e.g., Barthel index, BI); quality of life (e.g., EuroQoL-5D,
EQ-5D; EuroQol-Visual Analogue Scale, EQ-VAS); cogni-
tion (e.g., mini-mental state examination, MMSE; telephone
interview cognition scale, TICS; semantic fluency/animal
naming); mood (e.g., Zung depression scale, ZDS); and place
of residence. Safety measures comprised death and serious
adverse events (SAEs).
2.4. Data. Individual patient data for completed trials were
sought from each chief investigator, with data shared elec-
tronically (e.g., in Excel, SAS, or SPSS format). Data included
information on baseline factors: demographics, vascular
risk factors, haemodynamics, stroke type (ischaemic stroke;
ICH), stroke severity (e.g., Scandinavian Stroke Scale, SSS),
time from onset to randomisation (OTR, as a surrogate for
time to treatment), and use of thrombolysis and outcomes.
Data from each trial were compared with published results to
ensure integrity of the data and analyses.
2.5. Trial Quality. Trial quality followed Cochrane collabo-
ration criteria [23] and assessed the following components:
method of randomisation; allocation concealment; blinding
of treatment administration; blinding of outcome assessment;
completeness of outcome data; selective reporting; and any
other bias. The assessment for each component in the
included study was classified as “low risk,” “high risk,” or
“unclear risk” according to the Cochrane Handbook for
Systematic Reviews of Interventions [23].
2.6. Statistics. Since death is a common outcome after stroke
and to avoid missing an effect whereby a treatment might
improve both outcome and death, an extreme value was
added to the outcomes, as is done routinely for the mRS
(death = 6) and EQ-5D (death = 0); the following extreme
values were used for death: BI −5, animal naming −1, EQ-
VAS −1, TICS-M −1, tMMSE −1, HUS 0, mRS 6, and ZDS
102.5 [21]. The effect of treatment was assessed using binary
logistic regression (for binary data such as headache), Cox
regression (for time-to-event analyses, e.g., death), ordinal
logistic regression (OLR, for ordered categorical data, e.g.,
mRS), and multiple regression (for continuous or pseudo-
continuous data, e.g., SBP, BI).The assumption of proportion-
ality of odds forOLRwas tested using the likelihood ratio.The
effects of NO donor on subsequent events or outcomes are
expressed as odds ratio (OR) or mean difference (MD), with
95% confidence intervals. Statistical models incorporated
outcome adjusted for time from onset to randomisation,
age, sex, stroke type (ischaemic, haemorrhagic), stroke sever-
ity (SSS), stroke syndrome (TACS [24]), and systolic BP.
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The effect of treatment on the primary outcome (mRS) was
assessed in prespecified subgroups in all patients and in
those randomisedwithin 6 hours; subgroups were defined for
baseline variables: age (<70, ≥70 years), sex, stroke type (IS,
ICH), history of hypertension, history of stroke, stroke sever-
ity (SSS > 35, ≤35), mean systolic BP (<170, ≥170mmHg),
time from stroke to randomisation (<3, ≥3 hours), treatment
with alteplase, and trial. Subgroup analyses were performed
by adding an interaction term to an adjusted OLR model.
Data are number (%), median (interquartile range), or mean
(standard deviation). Analyses were performed using SAS
version 9.3; 𝑝 < 0.05 is considered significant.
3. Results
3.1. Included Trials. Eight studies involving nitric oxide
donors in acute stroke were identified. Of these, three were
excluded: a completed hospital-based uncontrolled study of
sodium nitroprusside [19], an ongoing prehospital ambu-
lance-based phase I uncontrolled study of GTN (http://clinical-
trials.gov/show/NCT01811693), and an ongoing prehospital
ambulance-based phase III randomised controlled study of
GTN (http://www.isrctn.com/ISRCTN26986053). The five
included studies were randomised controlled trials that
assessed GTN in patients with acute stroke (see Supplemen-
tal Figure I at Supplementary Material available online at
http://dx.doi.org/10.1155/2016/9706720), and individual patient
data were obtained for each [20, 21, 25–27]. Four trials were
small single centre phase II studies [20, 25–27] whilst the
largest one, ENOS [21], recruited 4011 patients from 173
sites across 23 countries (Supplemental Table I). One study
recruited patients from the community with paramedics
leading enrolment, consent, and initial treatment [20]; the
other four studies recruited from hospital-based stroke ser-
vices during the acute and subacute period after stroke
[21, 25–27]. When administered, intravenous thromboly-
sis was given after randomisation to GTN/control in the
ambulance-based trial and before randomisation in the large
hospital-based trial. One trial was placebo-controlled [25],
one was open-label [26], and the other 3 were single blind
[20, 21, 27]. All five studies administered GTN as a trans-
dermal patch at 5mg per day; one trial also tested 10mg
per day in a subgroup of 20 patients (Supplemental Table
I) [26]; due to the small number of patients randomised to
10mg and the finding that it had little extra effect on BP
[26], the influence of dose is ignored in the present analysis.
In addition to differences in design, the trials differed in
respect of patient characteristics including demographics
(age, sex distribution), medical history (hypertension, dia-
betesmellitus), systolic blood pressure, stroke (severity, type),
time from onset to randomisation, and use of alteplase
(Table 1).
3.2. Quality of the Evidence. The overall quality of the
included studies was good (Supplemental Table 1). Method
of randomisation was clearly reported in each study. Details
of BP recording, number of readings, and equipment used
were provided. Not all trials contributed to each outcome.
Outcome assessment was blinded, as listed in the trial
publications (and protocols when available). All participants
were accounted for and few patients were lost to follow-up.
3.3. Enrolled Patients. Altogether, the trials recruited a total
of 4197 participants with 2113 randomised to GTN and
2084 to no GTN (Table 1). The mean (standard deviation)
age was 70.4 (12.1) years with 2383 (56.8%) being male. A
history of hypertension, stroke, or ischaemic heart disease
was present, respectively, in 2700 (64.3%), 623 (15.0%), and
686 (16.5%) of patients. At baseline, 3976 (94.7%) patients
had an elevated BP (systolic BP > 140mmHg) and the mean
BPwas 167.1 (19.3)/89.5 (13.3)mmHg. 3502 (83.4%) of patients
had an ischaemic stroke and 646 (15.4%) an ICH. The mean
time from stroke onset to randomisation was 27.2 (16.1)
hours, and 312 (7.4%) patients were randomised within 6
hours of ictus. 435 (10.4%) of patients received thrombolytic
treatment. The characteristics of patients varied by time
to randomisation for several baseline characteristics: sex,
history of hypertension and ischaemic heart disease, stroke
severity (Scandinavian Stroke Scale), systolic and diastolic
blood pressure, heart rate, stroke type (ischaemic, ICH), and
treatment with alteplase (Supplemental Table II). In compari-
son with patients randomised later, those randomised within
6 hours were less likely to have diabetes and more likely to
have hypertension (systolic BP > 140mmHg), presentation
with an ICH, and have received rt-PA (if qualifying event
was an ischaemic stroke). In patients randomised within
6 hours, baseline characteristics were balanced apart from
a history of previous stroke and heart rate, both of which
were higher in those randomised to GTN (Supplemental
Table II).
3.4. Clinical Outcomes. Following first treatment, BP fell
by an average of 7.4/3.3mmHg at 1-2 hours with GTN as
compared to no GTN; in contrast, heart rate increased
by 1.9 bpm with GTN (Table 2). GTN was associated with
increased rates of headache (369/2033, 18.2% versus 171/2026,
8.4%) and clinical hypotension (i.e., hypotension requiring
medical intervention, 55/2033, 2.7% versus 15/2026, 0.7%).
There were no differences in the rates of death, deterioration,
recurrent stroke, clinical hypertension, or serious adverse
events by the end of the 7 to 12 days of randomised treatment.
Similarly, there were no differences in the rate of death
or institutionalisation or length of stay at discharge from
hospital (Table 2).
No differences were seen between GTN and no GTN for
any outcome measure recorded at day 90, including death,
dependency (mRS), disability (Barthel index), cognition
(MMSE, TICS, and semantic/animal naming), mood (ZDS),
or quality of life (EQ-5D as HUS, EQ-VAS). When assessed
in prespecified subgroups a time to treatment interaction was
present (𝑝 = 0.01) with patients treated with GTN within 6
hours having a better mRS score (Figure 1). Additionally, an
interaction with sex was present (𝑝 = 0.043) with efficacy
only apparent in women. No other subgroup interactions
were apparent, including age, vascular risk factors, stroke
type, stroke severity, systolic BP, time from onset to randomi-
sation, and use of alteplase.
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Age
Sex
Stroke type
History of hypertension
History of previous stroke
Stroke severity (/58)
Mean systolic blood pressure (mmHg)
Time to randomisation (hours)
Treatment with alteplase
Overall
Yes
Female
Male
Ischaemic
ICH
No
No
Yes
Present
Absent
≥70
<70
>48
24.1–48
12.1–24
6.1–12
≤6
≥170
<170
≤35
>35
1814
2383
1814
2383
3502
646
1497
2700
3537
623
2132
2028
2488
1708
312
440
1069
2260
113
435
3752
4197
Odds ratio and 95% CI N 2p
0.91
0.043
0.54
0.4
0.17
0.066
0.74
0.01
0.6
0.84
0.20 0.50 1.0 2.0 5.0
Favours GTN Favours No GTN
Figure 1: Effect of glyceryl trinitrate versus no glyceryl trinitrate on functional outcome (modified Rankin scale) at 90 days in predefined
subgroups of patients. Analyses are adjusted.
3.5. Outcomes by Time from Stroke to Randomisation. Anal-
ysis of mRS by time to randomisation showed no effect
beyond 5–10 hours and out to 50 hours, but apparent efficacy
(shift in mRS) with earlier treatment (Figure 2). 312 patients
were randomised within 6 hours of stroke onset, these
coming from two of the five trials (ENOS, RIGHT) [20,
21]. The earliest time from stroke to randomisation was 7
minutes. At 90 days, patients randomised to GTN within
6 hours had significant reductions in death, dependency
(lower mRS scores, Figure 3), disability (higher Barthel index
scores), andmooddisturbance (lowerZDS scores) andhigher
cognition scores (higher tMMSE and TICS scores) (Table 2).
Quality of life, semantic fluency (animal naming), death or
institutionalisation, and rate of serious adverse events did not
differ between the treatment groups.
No interactions between treatment and mRS in prespec-
ified subgroups were present (Supplemental Figure II). A
trend to more benefit in men than women (and the converse
across all studies and times to recruitment) is likely to reflect
chance. Significant shifts to less death or dependency were
seen with GTN for both haemorrhagic and ischaemic stroke
(Supplemental Figures III, IV). In patients with an ischaemic
stroke, a significant shift to less death or dependency was
seen for patients who received both GTN and thrombolysis
(Supplemental Figure V). However, benefit was not seen
in those with an ischaemic stroke who did not receive
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Figure 2: Effect of glyceryl trinitrate versus no glyceryl trinitrate on
functional outcome (modified Rankin scale) at 90 days by time to
randomisation.
No GTN
GTN
90 80 70 60 50 40 30 20 10 0100
(%)
6
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0
Figure 3: Distribution in modified Rankin scale scores at day 90 for
glyceryl trinitrate versus no glyceryl trinitrate in 312 patients with
any stroke and randomised within 6 hours of stroke onset. Common
odds ratio 0.52 (95% confidence intervals 0.34–0.78; 𝑝 = 0.002).
thrombolysis (Supplemental Figure VI); a trend to benefit
from GTN was seen in a post hoc unadjusted comparison
using a Mann-Whitney 𝑈 test (𝑝 = 0.092).
There was no overall evidence of benefit or harm, beyond
6 hours with GTN versus no GTN. Lower cognition scores
were apparent for patients randomised to GTN beyond 48
hours (Table 2). When considering the continuous relation-
ship between outcome and time to randomisation, time-
dependent effects of GTN were apparent in patients ran-
domised within 6 hours of onset for mRS, BI, EQ-5D, EW-
VAS, ZDS, and death (Figure 4).
4. Discussion
NO donors are a candidate treatment for acute stroke [18].
Five randomised controlled trials have assessed GTN, an
organic nitrate, in 4197 patients with acute ischaemic stroke
or ICH [20, 21, 25–27]. Overall, GTN had no effects on
functional outcome, disability, cognition, mood, quality of
life, or death. However, in comparison with no GTN, patients
randomised to GTN within 6 hours of stroke onset, a
prespecified subgroup [21], had a better outcome at day 90,
assessed using multiple markers of physical andmental func-
tional performance. Importantly, GTN appeared to improve
outcome in this subgroup in both ischaemic stroke and
ICH and in patients who received intravenous thrombolysis.
Further, very early treatment appeared to be safe in patients
enrolled without a stroke.
Although the apparent benefit seen in patients ran-
domised within 6 hours could reflect chance, several points
suggest the finding may be real. Firstly, beneficial effects of
very early administration of GTNwere seen independently in
two trial datasets: RIGHT (median time to treatment 55 min-
utes) and the ENOS subgroup treatedwithin 6 hours (median
time 258 minutes) had odds ratios for mRS of 0.08 (95% CI
0.02–0.41) and 0.57 (95% CI 0.37–0.89), respectively [20, 21].
Secondly, the effect was apparent in a study population of
more than 300 patients, a size similar to each of the positive
components of the NINDS trial of alteplase [28] and in a
recent trial of mechanical thrombectomy [5].Thirdly, a time-
dependent effect within the 6-hour time frame was apparent,
with the most potent effect seen in patients treated very
early during this period. Fourthly, a positive effect was seen
for multiple different outcomes covering death, dependency,
disability, cognition, mood, and quality of life. Fifthly, the
effect of treatment when given early was present across all
prespecified subgroups and was independent of stroke type
and severity and baseline BP. And last, the time-dependent
neuroprotective effect was also reported in a meta-analysis of
preclinical stroke studies of NO donors which showed that
studies treating within 60 minutes of initiation of ischaemia
were positive whereas those with a longer timewindow (up to
48 hours) were neutral [17]. Importantly, those variables that
differed between treatment groups in patients randomised
within 6 hours (history of previous stroke and heart rate,
both of which were higher with GTN) are unlikely to have
explained the differences in outcome seen in favour of GTN.
If hyperacute administration of GTN is beneficial after
stroke, then a number of potential mechanisms can be
postulated. Taken together, these actions may “buy time” and
protect the brain and prepare patients with ischaemic stroke
for thrombolysis. Circulating NO levels are low in acute
stroke [15, 16], perhaps due to local failure of production by
damaged endothelium; hence, immediate supplementation
might help restore this focal deficiency. A mechanism of
potential relevance to both ischaemic and haemorrhagic
stroke is that NO/GTN lowers BP in acute/subacute stroke
[20, 21, 25–27] and so may move hypertensive patients down
the “J-shaped” epidemiological curve relating BP and poor
functional outcome [29] towards its nadir. Lowering BP
might reduce early recurrence after ischaemic stroke and
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Figure 4: Continued.
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Figure 4: Effect of GTN on outcome by time to enrolment within 8 hours for (a)modified Rankin scale; (b) death; (c) Barthel index; (d) Euro-
Qol 5D (EQ-5D) health utility status; (e) Euro-QoL Visual Analogue Scale (EQ-VAS); (f) Zung depression scale; (g) telephone mini-mental
state examination; (h) telephone interview of cognition scale, modified (TICS-M); and (i) animal naming.
haematoma expansion in ICH [9, 30]. A number of additional
mechanisms apply to ischaemic stroke specifically. Firstly,
NO donors are neuroprotective in preclinical ischaemic
stroke [17], especially if given ultra-early. Secondly, NO
dilates cerebral arteries (e.g., middle cerebral) so it could
increase perilesional perfusion (via the “front door”) but
without inducing steal to other brain areas, as seen in the
GTN-3 pilot trial [27]. Thirdly, NO is a powerful dilator of
pial arteries (as shown experimentally [31]) and so might
increase tissue perfusion via the “backdoor” collateral system.
Fourthly, NO donors have anti-inflammatory effects, for
example, through reducing leukocyte adhesion. Fifthly, NO
donors can reduce thrombosis, as in microvessels. And
last, in addition to increases in blood levels of NO, other
potentially beneficial biochemical changesmay occur, as seen
experimentally and including increases in endothelial nitric
oxide synthase (NOS) and cyclic guanosine monophosphate
and reductions in neuronal NOS, nitrotyrosine, and adhesion
molecules [32–35].
Separately, GTN may “prime” patients for alteplase by
lowering their BP to below the licensed maximum of systolic
BP of 185mmHg, thereby allowing more to be treated, and
earlier, as hinted at in the RIGHTpilot trial [20]. Additionally,
GTN-induced cerebral arterial vasodilation may increase
access of alteplase to the obstructing clot and therefore
increase the effectiveness of thrombolysis. Hence, the effect
of GTN might be additive with alteplase, as suggested here
in patients who received both drugs. All of these poten-
tial mechanisms are likely to be time-dependent thereby
explaining why no positive findings were seen beyond 6
hours. And those mechanisms that improve blood flow
and perfusion mimic the time-dependent benefits seen with
intravenous thrombolysis and mechanical thrombectomy,
both of which improve outcome if delivered within 4.5 or 8
hours, respectively, of stroke onset [1–5].
This study has several strengths. Firstly, it uses individual
patient data from all identified completed controlled trials
of NO donors. Individual patient data meta-analyses are
considered the “gold standard” [36] since they allow for
covariate adjusted analyses (and so can adjust for any nonma-
jor imbalances at baseline) and facilitate analyses within sub-
groups; the present meta-analysis benefits in both respects.
Secondly, it includes a large cohort ofmore than 4000 patients
(comparable in size to a metaregression analysis of the effects
of thrombolysis assessed by time to randomisation [37]). And
last, it assesses safety and efficacy across a number of physical
and mental outcome domains; the results are similar across
all the studies outcome domains thereby exhibiting internal
consistency.
Several limitations are also apparent. First, all the data
relate to GTN and the results and conclusions may not apply
to other nitric oxide donors. Secondly, the majority of data
come from the ENOS trial (95.6% of all patients and 86.9%
of those randomised within 6 hours of onset) and therefore
its results dominate the analyses. Nevertheless, addition of
the four pilot trials extends the time windows examined in
the analyses; RIGHT tested ultra-acute prehospital treatment
(<4 hours with median time 55 minutes [20]) whilst the
three earlier pilot studies tested times beyond 48 hours.
Additionally, patient characteristics differed between the
trials and so improved external validity. Thirdly, one of the
trials was open-label [26] and three were single blind [20,
21, 27]. rather than double-masked (reflecting the lack of
availability from the late 1990s of placebo GTN patches from
commercial sources); although each trial used one or more
independent assessors blinded to treatment to record the
clinical outcomes, the potential for observer bias cannot be
ruled out. Additionally, GTN causes headache and this may
have unblinded some patients to their treatment assignment.
Further, treatment of headache might impact on outcome
although there no benefit was seen in a trial of paracetamol
[38]. Fourthly, the data all come from one research group and
it is important that other research groups study the role of
GTN in very early stroke. Last, a relatively small number of
patients were treated within 6 hours of stroke onset and these
come from just two [20, 21] of the five trials. The results in
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this prespecified subgroup must be considered provisional
and support the need for one or more large multicentre
trials recruiting patients in the ultra-acute period after stroke.
The RIGHT-2 trial is testing GTN for this indication in
850 patients recruited by paramedics in the prehospital
setting (http://right-2.ac.uk/) and other prehospital trials are
planned. Importantly, treatment before hospital admission
has the potential for modifying in-hospital diagnosis (e.g.,
converting ischaemic stroke into TIA) and severity, as seen
potentially in a trial of ambulance-based preconditioning
[39]. Similarly, prehospital treatment may modify the use
and need for hospital-based interventions.Whilst the RIGHT
trial showed a trend to more and earlier use of thrombolysis
[20], reduced neurovascular damage related to treatment
with GTN might reduce the need for other interventions
such as intra-arterial interventions or therapy; a hint of this
was seen in ENOS-early where there was a trend for less
physiotherapy in patients randomised to GTN [40].
5. Conclusions
In summary, NO donors in general and GTN specifically
do not improve outcome after acute and subacute stroke.
These results are similar to those seen for nitrates in acute
myocardial infarction [41, 42]. Nevertheless, the positive
finding in the prespecified subgroup of patients randomised
within 6 hours deserves further study, especially since GTN
is readily available, inexpensive, and easy to administer and
can be administered in the prehospital setting prior to brain
scanning.
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